193 related articles for article (PubMed ID: 35739366)
1. Efficacy of fibrin-rich platelets and leukocytes (L-PRF) in tissue repair in surgical oral procedures in patients using zoledronic acid-case-control study.
Parise GK; Costa BN; Nogueira ML; Sassi LM; Schussel JL
Oral Maxillofac Surg; 2023 Sep; 27(3):507-512. PubMed ID: 35739366
[TBL] [Abstract][Full Text] [Related]
2. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) in the management of a massive medication-related osteonecrosis of the jaw (MRONJ): A 5-years follow-up case report.
Giudice A; Antonelli A; Muraca D; Fortunato L
Indian J Dent Res; 2020; 31(5):813-818. PubMed ID: 33433526
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of drug-induced osteonecrosis of the jaws using platelet-rich fibrin: A clinical feasibility study.
Alrmali A; Saleh MHA; Kurdi SMS; Sabri H; Meghil MM; Wang HL
Clin Exp Dent Res; 2023 Oct; 9(5):791-798. PubMed ID: 37605488
[TBL] [Abstract][Full Text] [Related]
5. Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?
Park JH; Kim JW; Kim SJ
J Oral Maxillofac Surg; 2017 Jun; 75(6):1176-1184. PubMed ID: 28042979
[TBL] [Abstract][Full Text] [Related]
6. Complementarity of surgical therapy, photobiomodulation, A-PRF and L-PRF for management of medication-related osteonecrosis of the jaw (MRONJ): an animal study.
Jamalpour MR; Shahabi S; Baghestani M; Shokri A; Jamshidi S; Khazaei S
BMC Oral Health; 2022 Jun; 22(1):241. PubMed ID: 35717177
[TBL] [Abstract][Full Text] [Related]
7. Use of Leukocyte- and Platelet-Rich Fibrin in the Treatment of Medication-Related Osteonecrosis of the Jaws.
Maluf G; Caldas RJ; Silva Santos PS
J Oral Maxillofac Surg; 2018 Jan; 76(1):88-96. PubMed ID: 28675810
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw induced by bisphosphonates therapy in bone metastases patient: Case report and literature review.
Hao L; Tian Z; Li S; Yan K; Xue Y
Oral Oncol; 2022 May; 128():105852. PubMed ID: 35439709
[TBL] [Abstract][Full Text] [Related]
9. Use of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jaw.
Yalcin-Ülker GM; Duygu G; Tanan G; Cakir M; Meral DG
J Craniofac Surg; 2023 May; 34(3):1039-1044. PubMed ID: 36627754
[TBL] [Abstract][Full Text] [Related]
10. The use of Platelet-rich Fibrin in the management of medication-related osteonecrosis of the jaw: A case series.
Fernando de Almeida Barros Mourão C; Calasans-Maia MD; Del Fabbro M; Le Drapper Vieira F; Coutinho de Mello Machado R; Capella R; Miron RJ; Gomes Alves G
J Stomatol Oral Maxillofac Surg; 2020 Feb; 121(1):84-89. PubMed ID: 30794883
[TBL] [Abstract][Full Text] [Related]
11. The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study.
Zelinka J; Blahak J; Perina V; Pacasova R; Treglerova J; Bulik O
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2021 Sep; 165(3):322-327. PubMed ID: 32597421
[TBL] [Abstract][Full Text] [Related]
12. The role of leukocyte and platelet-rich fibrin in the prevention of medication-related osteonecrosis of the jaw, in patients requiring dental extractions: an observational study.
Besi E; Pitros P
Oral Maxillofac Surg; 2024 Jun; 28(2):785-793. PubMed ID: 38182917
[TBL] [Abstract][Full Text] [Related]
13. Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin.
Özalp Ö; Yıldırımyan N; Öztürk C; Kocabalkan B; Şimşek Kaya G; Sindel A; Altay MA
BMC Oral Health; 2021 Dec; 21(1):613. PubMed ID: 34852823
[TBL] [Abstract][Full Text] [Related]
14. Use of Leukocyte- and Platelet-Rich Fibrin to Prevent Osteonecrosis of the Jaws Associated with the Use of Bisphosphonate Therapy: A Case Series.
Stresser FA; Parise GK; Macedo FJ; Sassi LM; Schussel JL
J Maxillofac Oral Surg; 2023 Dec; 22(4):1159-1165. PubMed ID: 38105812
[TBL] [Abstract][Full Text] [Related]
15. The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ).
Miranda M; Gianfreda F; Raffone C; Antonacci D; Pistilli V; Bollero P
Biomed Res Int; 2021; 2021():4948139. PubMed ID: 34095295
[TBL] [Abstract][Full Text] [Related]
16. Platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: a clinical and histopathological evaluation.
Inchingolo F; Cantore S; Dipalma G; Georgakopoulos I; Almasri M; Gheno E; Motta A; Marrelli M; Farronato D; Ballini A; Marzullo A
J Biol Regul Homeost Agents; 2017; 31(3):811-816. PubMed ID: 28958140
[TBL] [Abstract][Full Text] [Related]
17. The use of advanced-platelet rich fibrin (A-PRF) in the management of medication-related osteonecrosis of the jaw (MRONJ): A case report.
Asfour MAR; Aljoujou AA; Saifo MS; Jabban HAL
Clin Case Rep; 2023 Nov; 11(11):e8259. PubMed ID: 38028038
[TBL] [Abstract][Full Text] [Related]
18. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
19. Autologous platelet-rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication-related osteonecrosis of the jaw.
Bennardo F; Bennardo L; Del Duca E; Patruno C; Fortunato L; Giudice A; Nisticò SP
Dermatol Ther; 2020 May; 33(3):e13334. PubMed ID: 32219975
[TBL] [Abstract][Full Text] [Related]
20. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
